Ayala Pharmaceuticals, Inc.
DelistedCIK 1100397fmd_10XGT4Y3WDEH9G7JMETRNGTFF3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2003 to Dec 31, 2023, 64 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 4 | 12 | 6 | 21 | 0 | 3 | 0 | – | 0 |
| Cost of revenue | – | – | – | – | – | – | – | – | 1 | 0 |
| Gross profit | – | – | – | – | – | – | – | – | 0 | 0 |
| Research and development | 24 | 49 | 71 | 57 | 27 | 16 | 11 | – | 28 | 24 |
| Total operating expenses | 49 | 80 | 110 | 76 | 39 | 27 | 22 | 20 | – | – |
| Operating income | (49) | (76) | (98) | (70) | (18) | (26) | (19) | – | (38) | (36) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (0) | (0) | (0) | – | (0) | – | 0 | (16) |
| Income before taxes | (49) | (76) | (98) | (66) | (17) | (26) | (18) | – | (37) | (52) |
| Income tax expense | (2) | (3) | (4) | 0 | 0 | 0 | 0 | – | 1 | (4) |
| Net income from continuing operations | (47) | (74) | (93) | (67) | (17) | (26) | (18) | – | (38) | (48) |
| Net income | (47) | (74) | (93) | (67) | (17) | (26) | (18) | – | (38) | (48) |
| Net income to common shareholders | – | – | – | – | – | – | (18) | – | (38) | (48) |